TP53 and acute myeloid leukemia: The vast majority of ITD/ITD; p53+/− mice developed AML (65%) and acute lymphoblastic leukemia (ALL, 24%) (Figs. 1d and 2a, b), while AML was observed only in 17% of ITD/ITD mice (others developed CMML-like disease (57%, Fig. 2a) and acute lymphoblastic leukemia (ALL, 24%)), and p53+/− mice mainly developed solid tumors (55%) and lymphoma (13%) as reported previously (Fig. 1d; Supplementary Fig. 4) [18].